Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Clinical trial NCT03298451 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03298451
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-10-11
- Primary completion
- 2021-08-27
- Enrollment
- 1324
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.